The pharmaceutical industry’s communication strategy to the medical profession, including the patient, has evolved considerably in the last two decades. Digitalisation is obviously at the heart of this (r)evolution by facilitating direct outreach to the public but it is only one aspect of it. True fund trends, echoing equally important societal trends, affect how Big Pharma communicates. But that's not all! Health-related issues (increasing interest in the patient and the growing importance of chronic diseases), R&D techniques (the advent of Big Data, personalized treatments) and other aspects contribute to this revolution.
While the offer has changed significantly, the doctor's request has also greatly changed focusing increasingly on the content he seeks, willingly swinging between different contents and looking for “efficiency”. Pharmaceutical companies and other stakeholders are not left out. Between "supply" and "demand", between "promotion" and "education", a world is changing ... The third edition of this Digital Pharma summit will feature this.